Morgan Stanley
AARD

Morgan Stanley’s Aardvark Therapeutics AARD Stock Holding History

Morgan Stanley’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Buy
30,177
+12,615
+72% +$58.9K ﹤0.01% 6010
2026
Q1 		$66.2K Sell
17,562
-60,392
-77% -$626K ﹤0.01% 6307
2025
Q4 		$1.02M Buy
77,954
+9,492
+14% +$118K ﹤0.01% 5179
2025
Q3 		$910K Buy
68,462
+59,502
+664% +$671K ﹤0.01% 5218
2025
Q2 		$121K Buy
8,960
+6,742
+304% +$69.5K ﹤0.01% 6064
2025
Q1 		$16.7K Buy
+2,218
New +$24.9K ﹤0.01% 6635

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Morgan Stanley's AARD Position: Q2 2026 in Review

Morgan Stanley increased its Aardvark Therapeutics (AARD) stake by 72% in Q2 2026, buying an estimated $58.9K and bringing the position to 30,177 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #6010.

Morgan Stanley first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.02M in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Morgan Stanley held 30,177 shares of Aardvark Therapeutics worth $174K as of Q2 2026.
  • Morgan Stanley bought 12,615 Aardvark Therapeutics shares in Q2 2026, an estimated $58.9K.
  • Aardvark Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6010 holding.
  • Morgan Stanley first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Morgan Stanley's Aardvark Therapeutics position peaked at $1.02M in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.